Increases in triglyceride levels are associated with clinical response to clozapine treatment

2013 ◽  
Vol 27 (4) ◽  
pp. 401-403 ◽  
Author(s):  
John Lally ◽  
Anne Gallagher ◽  
Emma Bainbridge ◽  
Gloria Avalos ◽  
Mohamed Ahmed ◽  
...  
1996 ◽  
Vol 39 (7) ◽  
pp. 529
Author(s):  
R. Bera ◽  
A.H. Kalali ◽  
B. Gulasekaram ◽  
S. Hayes ◽  
Y. Jin ◽  
...  

1995 ◽  
Vol 40 (4) ◽  
pp. 208-211 ◽  
Author(s):  
G. Honer William ◽  
G. William Macewan ◽  
Lili Kopala ◽  
Siemion Altman ◽  
Sherri Chisholm-Hay ◽  
...  

Objective To study the clinical response to clozapine in patients with refractory schizophrenia. Method Open trial of clozapine in 61 consecutively-treated patients. Results Following clozapine, the level of function of patients was improved relative to admission (p = 0.0001) and to the highest level in the previous year (p = 0.0001). Severity of illness was decreased (p = 0.0001). Overall, 31% of the patients were classified as responders to clozapine and the responders were all identified by 32 weeks of treatment. Poor functioning in the previous year was associated with less favourable response. At a mean interval of 26 months following discharge, 72% of the patients were continuing clozapine treatment. Conclusions This open trial of patients who were treated consecutively indicates a comparable degree of response to clozapine as observed in controlled clinical trials, and that level of functioning in the previous year was the best predictor of response.


2015 ◽  
Vol 5 (2) ◽  
pp. 74-77
Author(s):  
Dongmi Kim

Abstract Since its initial landmark trial against chlorpromazine in 1988, clozapine has been the drug of choice for the treatment of refractory schizophrenia. However, variability in clinical response to clozapine treatment is unequivocal. In an effort to preselect patients who are most likely to benefit from clozapine, a number of patient and disease variables and select genetic differences have been studied for their association with positive treatment response to clozapine. Because of small trial sizes and the heterogeneity of study design, findings have resulted in no generalizable conclusion. Future pharmacogenetic studies hold the promise of antipsychotic treatment personalization.


2010 ◽  
Vol 20 (3) ◽  
pp. 76-83 ◽  
Author(s):  
Joseph Donaher ◽  
Tom Gurrister ◽  
Irving Wollman ◽  
Tim Mackesey ◽  
Michelle L. Burnett

Parents of children who stutter and adults who stutter frequently ask speech-language pathologists to predict whether or not therapy will work. Even though research has explored risk-factors related to persistent stuttering, there remains no way to determine how an individual will react to a specific therapy program. This paper presents various clinicians’answers to the question, “What do you tell parents or adults who stutter when they ask about cure rates, outcomes, and therapy efficacy?”


2001 ◽  
Vol 120 (5) ◽  
pp. A253-A253
Author(s):  
V YANG ◽  
R CASERO ◽  
D GEIMAN ◽  
W HUBBARD ◽  
L HYLIND ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document